Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe
Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension to the Avastin (bevacizumab) breast cancer label in Europe. The application proposed the use of Avastin in combination with Xeloda (capecitabine) for the first-line treatment of women with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes and anthracyclines is not considered appropriate. Avastin is already approved in Europe in combination with paclitaxel chemotherapy in this setting.

The submission to expand the label was based on results from the phase III RIBBON 1 study which showed a significant increase in the length of time women lived without their disease getting worse (progression-free survival) when Avastin was combined with capecitabine compared to those who received capecitabine alone.

The current EU Avastin licence for metastatic breast cancer is for combination use with paclitaxel chemotherapy. However taxane-based chemotherapy is not suitable for all patients. The RIBBON 1 study showed that Avastin in combination with capecitabine could give these women an additional first-line therapy choice. Final approval from the European Commission is expected later this year.

“We are pleased the CHMP has determined that Avastin in combination with capecitabine provides a meaningful clinical benefit in metastatic breast cancer, affording physicians and patients more choice in selecting an appropriate treatment option,” said Hal Barron M.D., Chief Medical Officer and Head, Global Product Development. “Avastin is the only anti-angiogenic therapy approved to treat HER2-negative metastatic breast cancer in Europe and the capecitabine data from the RIBBON 1 study, which was the basis of this positive opinion, add to the clinical evidence supporting the use of Avastin as a treatment for this disease”
RIBBON 1 showed that Avastin in combination with capecitabine resulted in:

- A 45 percent increase in the likelihood of women being alive without disease progression compared to those who received capecitabine alone (hazard ratio=0.69; p=0.0002).
- A median PFS of 8.6 months compared to 5.7 months in those women that received capecitabine alone.
- 35.4% of women experiencing a major shrinkage of their tumour compared to 23.6% of those receiving capecitabine alone (p= 0.0097).

RIBBON 1 adds to the existing clinical evidence demonstrating the benefits of Avastin in metastatic breast cancer. The pivotal E2100 (Avastin and paclitaxel) study forms the basis of the currently approved EU label allowing combination of Avastin with paclitaxel to treat women with metastatic breast cancer.

**About Avastin: Over 5 Years of Transforming Cancer Care**

With the initial approval in the USA for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced cancer. Today, Avastin is continuing to transform cancer care through its proven survival benefit (overall survival and/or progression free survival) across several types of cancer. Avastin is approved in the US and Europe for the treatment of advanced stages of colorectal cancer, breast cancer, non-small cell lung cancer and kidney cancer, and Avastin is also available in the US and over 31 other countries for the treatment of patients with glioblastoma (a type of brain cancer). Avastin is the only anti-angiogenic therapy available for the treatment of these numerous advanced cancer types, which collectively cause over 2.5 million deaths each year.

Avastin has made anti-angiogenic therapy a fundamental pillar of cancer treatment today – over three quarters of a million patients have been treated with Avastin so far. A comprehensive clinical programme with more than 500 ongoing clinical trials is investigating the use of Avastin in over 50 tumor types (including colorectal, breast, non-small cell lung, brain, gastric, ovarian and others) and different settings (advanced or early stage disease).

**About Avastin: Mode of Action**

Avastin is an antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body. Avastin’s precise mode of action allows it to be combined effectively with a broad range of chemotherapies and other anti-cancer treatments. Avastin helps
to control tumor growth and extend survival with only a limited impact on the side effects of chemotherapy.

**About Xeloda (capecitabine)**

Xeloda (capecitabine) is a highly effective targeted oral chemotherapy offering patients a survival advantage when taken on its own or in combination with other anticancer drugs. Xeloda uniquely activates the cancer-killing agent 5-FU (5-fluorouracil) directly inside the cancer cells. Xeloda tablets can be taken by patients in their own home, reducing the number of hospital or clinic visits.

Licensed and marketed by Roche in more than 100 countries worldwide, Xeloda has over 11 years proven clinical experience providing an effective and flexible treatment option to over 1.8 million people with cancer. Xeloda is currently approved in:

**Metastatic Breast Cancer**
- Monotherapy in patients with tumours resistant to taxanes and anthracyclines – (US) 1998 and (EU) 2002
- In combination with docetaxel in patients whose disease has progressed following IV chemotherapy with anthracyclines – (US) 2001 and (EU) 2002
- In patients with inoperable or recurrent breast cancer – (Japan) 2003

**Metastatic Colorectal Cancer**
- Monotherapy first-line (US, EU and ROW) – 2001
- In combination with any chemotherapy in all lines of treatment with or without Avastin (EU/ROW) – 2008
- In combination with oxaliplatin for the treatment of patients with advanced or refractory colorectal cancer who are not candidates for curative surgery (Japan) – 2009

**Adjuvant Colon Cancer**
- Monotherapy (US & EU) – 2005
- Monotherapy (Japan) – 2007
- In combination with oxaliplatin as XELOX (EU) – 2010

**Advanced Gastric Cancer**
- First-line treatment (South Korea) – 2002
- In combination with platinum-based chemotherapy first-line (EU and ROW) – 2007
About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Additional information
- Roche in Oncology: www.roche.com/media/media_backgrounder/media_oncology.htm

Roche Group Media Relations
Phone: +41 -61 688 8888 / e-mail: basel.mediaoffice@roche.com
- Alexander Klauser (Head)
- Silvia Dobry
- Daniel Grotzky
- Claudia Schmitt
- Annette Walz